Treating atopic-dermatitis-like skin lesions in mice with gelatin-alginate films containing 1,4-anhydro-4-seleno-D-talitol (SeTal)

Guilherme T. Voss, Michael J. Davies, Carl H. Schiesser, Renata L. de Oliveira, Andresa B. Nornberg, Victória R. Soares, Angelita M. Barcellos, Cristiane Luchese, André R. Fajardo*, Ethel A. Wilhelm

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstract

New compounds and pharmacological strategies offer alternatives for treating chronic skin diseases, such as atopic dermatitis (AD). Here, we investigated the incorporation of 1,4-anhydro-4-seleno-D-talitol (SeTal), a bioactive seleno-organic compound, in gelatin and alginate (Gel-Alg) polymeric films as a strategy for improving the treatment and attenuation of AD-like symptoms in a mice model. Hydrocortisone (HC) or vitamin C (VitC) were incorporated with SeTal in the Gel-Alg films, and their synergy was investigated. All the prepared film samples were able to retain and release SeTal in a controlled manner. In addition, appreciable film handling facilitates SeTal administration. A series of in-vivo/ex-vivo experiments were performed using mice sensitized with dinitrochlorobenzene (DNCB), which induces AD-like symptoms. Long-term topical application of the loaded Gel-Alg films attenuated disease symptoms and pruritus, with suppression of the levels of inflammatory markers, oxidative damage, and the skin lesions associated with AD. Moreover, the loaded films showed superior efficiency in attenuating the analyzed symptoms when compared to hydrocortisone (HC) cream, a traditional AD-treatment, and decreased the inherent drawbacks of this compound. In short, incorporating SeTal (by itself or with HC or VitC) in biopolymeric films provides a promising alternative for the long-term treatment of AD-type skin diseases.

OriginalsprogEngelsk
Artikelnummer123174
TidsskriftInternational Journal of Pharmaceutics
Vol/bind642
Antal sider13
ISSN0378-5173
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
We are grateful for financial support from Seleno Therapeutics Pty. Ltd., and grants and scholarships from the following agencies: CNPq (429859/2018-0, 312747/2020-9), FAPERGS (PqG 21/2551-0001943-3 and 21/2551-0002162-4), CAPES, the Independent Research Fund Denmark (Danmarks Frie Forskningsfond; DFF-7014-00047) and the Novo Nordisk Foundation (NNF13OC0004294 and NNF20SA0064214). CNPq is also acknowledged for fellowships to A.R.F., E.A.W. and C.L. This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brazil (CAPES) - Finance Code 001, and forms part of the activities of the International SeS Redox and Catalysis Network.

Publisher Copyright:
© 2023 Elsevier B.V.

Citationsformater